Human antibodies to human immunodeficiency virus-1 (HIV-1) can neutralize a broad range of viral isolates in vitro and protect non-human primates against infection 1, 2 . Previous work showed that antibodies exert selective pressure on the virus but escape variants emerge within a short period of time 3, 4 . However, these experiments were performed before the recent discovery of more potent anti-HIV-1 antibodies and their improvement by structurebased design [5] [6] [7] [8] [9] . Here we re-examine passive antibody transfer as a therapeutic modality in HIV-1-infected humanized mice. Although HIV-1 can escape from antibody monotherapy, combinations of broadly neutralizing antibodies can effectively control HIV-1 infection and suppress viral load to levels below detection. Moreover, in contrast to antiretroviral therapy [10] [11] [12] , the longer half-life of antibodies led to control of viraemia for an average of 60 days after cessation of therapy. Thus, combinations of potent monoclonal antibodies can effectively control HIV-1 replication in humanized mice, and should be re-examined as a therapeutic modality in HIV-1-infected individuals.
Treatment of HIV-1 infection was ineffective until antiretroviral drugs were applied in combination, permitting sustained suppression of viraemia 13, 14 . Despite this resounding success, the burden of daily medication, side effects and resistance to antiretroviral drugs necessitate a continuing search for additional complementary therapeutic modalities 15 .
To examine the potential of recently discovered antibodies to control HIV-1 infection effectively, we used non-obese diabetic (NOD) mice that carry targeted disruptions of the recombinase activating gene 1 (Rag1
2/2
) and interleukin receptor common gamma chain (Il2rg null ) reconstituted with human fetal liver-derived CD34
1 haematopoietic stem cells 16, 17 . Humanized mice were preferred to non-human primates for these experiments because the latter produce anti-human antibodies that can alter the bioavailability of the injected human antibodies after only one to 2 weeks.
Humanized mice were analysed for engraftment ( Supplementary  Fig. 1 ) and infected intraperitoneally (i.p.) with a CCR5-tropic HIV-1 isolate (NL4-3 carrying a YU2 envelope; HIV-1 YU2 ) 18 . Viral load in plasma was determined by quantitative polymerase chain reaction with reverse transcription (qRT-PCR) with a limit of detection of 800 copies ml 21 ( Supplementary Fig. 2 ). Viraemia was established (geometric mean of 1.06 3 10 5 copies ml
21
) by 14-20 days, and was stable for 60 days before decreasing to a geometric mean of 1.6 3 10 4 copies ml 21 at 120 days after infection (Fig. 1a) . Persistent viraemia was associated with progressive reduction in CD4 1 T cells as measured by decreasing CD4
1 to CD8 1 T-cell ratios ( Supplementary Fig. 3 ).
To confirm that HIV-1 YU2 infection in humanized mice is associated with viral diversification 19 , we cloned and sequenced 68 gp120 envelopes from 10 infected mice (Fig. 1a) . After accounting for randomly introduced PCR errors ( Supplementary Fig. 4a and b) , we observed an average of 3.2 nucleotide substitutions per gp120 sequence, corresponding to a substitution rate of 2.2 3 10 23 bp 21 ( Supplementary  Fig. 4b ). We conclude that HIV-1 YU2 infection is well established by 14-20 days in humanized mice, it persists for several months, and the virus mutates generating viral swarms 18, 19 .
To examine the effects of broadly neutralizing antibodies on established HIV-1 infection, we treated groups of HIV-1 YU2 -infected mice with antibody monotherapy using five different broadly neutralizing antibodies. The antibodies were selected based on their potency and breadth in in vitro neutralization assays and because they target different epitopes. [45] [46] G54W is the most potent anti-CD4 binding site (CD4bs) antibody reported so far 5 , PG16 targets the V1/V2 loop region 8, 20 , PGT128 is a glycan-dependent anti-V3 loop antibody 7 , and 10-1074 is a more potent variant of PGT121 (refs 7, 30 ) that has no measurable affinity for protein-free complex-type N-glycans in microarrays 30 . 3BC176 recognizes a conformational, yet-to-be-defined epitope, and neutralizes HIV-1 strains that are resistant to potent CD4bs antibodies 21 . Mice were treated subcutaneously with 0.5 mg of antibody per mouse (,20 mg kg
) either once or twice a week based on the antibodies' half-life in mice, which varied from 0.7 to 6.3 days (Supplementary Fig. 5 ).
At 6-7 days after the initiation of therapy, mice treated with PGT128 or 10-1074 showed an average decrease of 1.1 log 10 (P # 0.05) and 1.5 log 10 (P # 0.01) HIV-1 RNA copies ml 21 , respectively (Fig. 1b, c , whereas no effect was detected for 3BC176. However, with the exception of one mouse receiving 10-1074, viraemia rebounded after 14-16 days and no significant differences between treated and control groups were detected thereafter (Fig. 1b, c) . We conclude that monotherapy with PG16, 45-46 G54W , PGT128 or 10-1074 results in an only transient decrease in the viral load in humanized mice infected with HIV-1 YU2 .
To determine whether viral escape from monoclonal antibody therapy is linked to specific mutations, we cloned and sequenced gp120 from HIV-1 YU2 -infected mice before ( Supplementary Fig. 6 ) and after ( Supplementary Fig. 7 ) viral rebound. In all cases, viral rebound was associated with recurring mutations (defined as substitutions within a range of 3 amino acids in a majority of gp120 clones in more than one mouse) in residues that map to the antibody target sites (Fig. 1d , Supplementary Fig. 7 and Supplementary Table 2b ). For example, escape from 45-46 G54W was linked to mutations in residues 276-281, 458 or 459, which are located in or near the CD4bs 22 . Likewise, escape from PG16 was associated with mutations at residues 160 or 162, which correspond to the potential N-linked glycosylation site (PNGS) in the V1/V2 loop 8, 20 . Escape from PGT128 and 10-1074 was associated with mutations at residues 332 or 334, both of which abrogate the same PNGS (Fig. 1d, Supplementary Fig. 7 and Supplementary Table 2b).
To verify that the putative escape mutations rendered HIV-1 YU2 resistant to the respective antibodies, we produced selected HIV-1 YU2 pseudoviruses carrying the mutations and tested them in neutralization assays in vitro. Tested recurrent mutations associated with escape were always associated with specific resistance to their respective antibodies ( Supplementary Fig. 8 ). Passenger mutations, defined as occurring in only a single mouse, or in multiple mice but in fewer than 50% of gp120 sequences in those mice, had no apparent effect on viral sensitivity to the antibodies ( Supplementary Fig. 8 ).
Although escape mutations were associated with antibody-targeted epitopes, some gp120 residues seemed to tolerate multiple alternative amino acid substitutions, whereas others were more restricted. For example, in humanized mice treated with 45-46 G54W , N279 mutated to H, K, or I, but A281 only became T ( Fig. 1d and Supplementary Table 2b ). Escape from PGT128 was associated with replacement of N332 with K, S, T or Y, whereas it became K in 51 out of 52 sequences from 4 humanized mice treated with 10-1074 (Fig. 1d , Days   ID4  ID10  ID19  ID24  ID26  ID27   ID35   ID33   ID42  ID68  ID81  ID138  ID179 Table 1 ). The dotted line represents the limit of detection for viral load determination (800 copies ml 21 ). The right panel shows changes in log 10 (RNA copies ml ) 6-7 days and 27-32 days after treatment initiation. Columns and error bars represent mean and standard deviation, respectively. Significant statistical differences among groups were determined by performing a Kruskal-Wallis test with Dunn multiple comparison post-hoc test using GraphPad Prism version 5.0b for Mac OS X, GraphPad software. Significant differences among groups were detected at day 6-7 but not at the later time point (27-32 days) . Asterisks (*P # 0.05; **P # 0.01) indicate a significant difference compared to the control group. d, Sequence analysis of HIV-1 gp120 after viral rebound while on therapy with single broadly neutralizing antibodies (Supplementary Fig. 7 ). Pie charts show the distribution of amino acid changes at recurrently mutated sites. A selection of amino acid substitutions was tested in vitro and confirmed antibody escape ( Supplementary Fig. 8 and Supplementary Table 2b ). Mutations are relative to HIV-1 YU2 and numbered according to HXBc2. The total numbers of analysed mice/gp120 sequences are indicated in the centre of the charts ( Supplementary  Fig. 7 and Supplementary Table 2b ).
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6 D E C E M B E R 2 0 1 2 | V O L 4 9 2 | N A T U R E | 1 1 9 and Supplementary Table 2b ). Consistent with this observation, N332K is resistant to both PGT128 and 10-1074, whereas N332Y is resistant to PGT128 but remains sensitive to high concentrations of 10-1074 ( Supplementary Fig. 8 ).
Because the selected broadly neutralizing antibodies target distinct epitopes on the HIV-1 spike, we investigated whether treatment with a combination of three (tri-mix: 3BC176, PG16 and 45-46 G54W ) or five (penta-mix: 3BC176, PG16, 45-46 G54W , PGT128 and 10-1074) antibodies would alter the course of infection (Fig. 2 and Supplementary Table 1 ). These combinations neutralize all but 2 (tri-mix 98.3%) and 1 (penta-mix 99.2%) of 119 mostly tier 2 and 3 viruses from multiple clades with an IC 80 (geometric mean) of 0.121 mg ml 21 and 0.046 mg ml 21 for tri-mix and penta-mix, respectively ( Supplementary Fig. 9 ). A decline in the initial viral load was seen in 11 out of 12 tri-mixtreated mice, but 7 rebounded to pre-treatment levels (Fig. 2a,  Supplementary Table 1c and Supplementary Fig. 10 ). In contrast to monotherapy where mice almost never controlled viraemia beyond 2 weeks of therapy, the tri-mix treatment led to prolonged and effective HIV-1 control in 3 of 12 animals. In 2 of these mice viral load rebounded 20-40 days after cessation of therapy at a time when the YU2 gp120-reactive antibody concentration in serum decreased to a level below detection (Fig. 3a) . In the third mouse (ID21), viraemia was detected but remained low even in the absence of therapy for 60 days.
Sequences obtained from mice that experienced viral rebound while on tri-mix therapy showed a combination of the mutations found in the PG16 and 45-46 G54W monotherapy groups (Figs 1d and 2b, c and  Supplementary Tables 2b and 3a) . We verified that these mutations rendered HIV-1 YU2 resistant to PG16 and 45-46 G54W by producing the corresponding mutant pseudoviruses and testing them in neutralization assays in vitro (Supplementary Fig. 8 ). The pseudoviruses were not resistant to 3BC176, confirming that this antibody did not exert selective pressure on HIV-1 YU2 and therefore only 2 of the 3 antibodies in the tri-mix were efficacious.
In contrast, sequences obtained from the mice that exhibited sustained viral control and rebounded after cessation of therapy either lacked any broadly neutralizing antibody-associated mutation, or had a mutation mapped to the 45-46 G54W (K282R) or PG16 (N162P) target site, but not both ( Fig. 3b and Supplementary Table 3a) . In these mice, rebound viraemia only occurred after YU2 gp120-reactive antibody levels decreased to below detection, indicating that the viruses that emerged were latent and remained susceptible to the tri-mix. All 14 mice treated with the penta-mix treatment showed a decrease in viral load 6-7 days after initiation of therapy ( Fig. 2d and Supplementary Table 1d ). However, in contrast to monotherapy and the tri-mix, all of the penta-mix-treated mice remained below baseline viral loads during the entire treatment course (Fig. 2d , Supplementary Table 1d and Supplementary Fig. 10 ). Of 13 mice (one died), 11 had viral loads below or near the limit of detection. The two mice with the slowest reduction in viral load during treatment showed signs of severe graft versus host disease. We conclude that penta-mix therapy reduces the viral load to levels below detection for up to 60 days in HIV-1 YU2 -infected humanized mice.
Penta-mix therapy was discontinued after 31-60 days and the mice were monitored for an additional 100 days (Fig. 3c) . In 7 out of 8 mice that survived, viraemia rebounded after an average of 60 days (Fig. 3c) . In contrast, mice treated with antiretroviral therapy rebound after 10 days following discontinuation of therapy 12 . Viral rebound in penta-mix-treated mice was always correlated with decreased levels of the administered antibodies (Fig. 3c) . Only one tri-mix (ID21) and one penta-mix (ID129) mouse did not rebound. To determine their ability to support HIV-1 infection, these mice were re-infected with HIV-1 YU2 (57.5 ng p24) and measured for viral load 2 weeks later. One of the two mice became infected but only at very low levels compared to the initial infection ( Supplementary Fig. 11 ). Therefore, prolonged control was primarily due to the long half-life of the injected antibodies. ID128  ID129  ID130  ID132  ID133  ID134  ID143  ID144  ID161  ID164  ID182  ID187  ID194   0  2 Table 1c ). Infection and viral load determination was performed as in Fig. 1 . The right panel shows changes in log 10 (RNA copies ml
21
) from baseline at day 0. Red and green lines represent the average values in viral load change of tri-mix and control group (Fig. 1a) , respectively. b, Individual gp120 envelope sequences cloned from single mice (y axis) during tri-mix therapy after viral rebound. gp120 sequences are represented by horizontal grey bars with silent mutations indicated in green and amino acid replacements in red. Black asterisks represent mutations generating a stop codon and bold grey bars deletions. All mutations are relative to HIV-1 YU2 and numbered according to HXBc2. Selected mutations at sites highlighted in blue can confer resistance to PG16-or 45-46 G54W -mediated neutralization in vitro ( Supplementary Fig. 8 and Supplementary Table 3a) . c, Pie charts as in Fig. 1d illustrate distribution of amino acid changes in gp120 (b) at PG16 (left) or 45-46 G54W (right) respective target sites (Supplementary Table 3a) . d, As in a, for HIV-1 YU2 -infected humanized mice treated with a combination of 3BC176, PG16, 45-46 G54W , PGT128 and 10-1074 (penta-mix; grey shading, Supplementary Table 1d ). Mouse ID72 (tri-mix) and ID126 (penta-mix) died early and are not displayed.
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We attempted to clone gp120 sequences from the plasma and cellassociated RNA of all penta-mix mice. Although we succeeded in obtaining sequences from three mice during the treatment period, every sequenced clone had at least one in-frame stop codon, all of which were consistent with signature APOBEC3G/F mutations ( Supplementary Fig. 12 and Supplementary Table 3b ). In contrast, 27 out of 28 gp120 sequences from viruses cloned after therapy was stopped and viral load rebounded did not have stop codons (Fig. 3d  and Supplementary Table 3b) . Furthermore, viruses that rebounded carried no or only one signature resistance mutation and remained susceptible to the penta-mix as viraemia was controlled by re-treatment (Fig. 3e) . Therefore, humanized mice treated with the penta-mix were unable to escape antibody pressure by way of envelope mutations, but the virus remained latent throughout the treatment period in at least 7 out of 8 mice.
HIV-1 infection in humanized mice differs from HIV-1 infection in humans in a number of important respects including a lower total viral load and a near absence of antibody-mediated immune responses, and therefore there is no pre-existing selective pressure on the envelope 18 ( Supplementary Fig. 13 ).
Previous antibody therapy experiments in humanized mice and humans concluded that treatment with combinations of antibodies had only limited effects against established HIV-1 infection 4, 23, 24 . However, the broadly neutralizing antibodies used in those experiments (that is, in mice b12, 2G12, 2F5; in humans 2G12, 4E10, 2F5) were orders of magnitude less potent than the ones used in this study. The difference in potency and the extended combination of broadly neutralizing antibodies probably account for the differences between our findings and earlier work.
Combination antibody therapy resembles antiretroviral, antimicrobial or anti-tumour combined therapy, in that escape requires the improbable appearance of multiple simultaneous mutations. However, antibodies differ from other therapeutic modalities for HIV in several respects. First, they can neutralize the pathogen directly; second, they have the potential to clear the virus and infected cells through engagement of innate effector responses 25 ; third, immune complexes produced by the passively transferred antibodies may enhance immunity to HIV-1 26 ; and fourth antibodies have far longer half-lives than currently used antiretroviral drugs. Finally, anti-HIV-1 antibodies can be stably expressed in mammalian hosts for many months using adenoassociated viruses and therefore the potential exists to prolong their bioavailability further 27, 28 . Although we have not combined antibodies and small molecule antiretroviral drugs, we speculate that such combinations may be particularly effective because antibodies add a new modality to existing therapies. In addition, a combination of highly potent antibodies may be effective in suppressing viraemia in individuals who do not tolerate anti-HIV medication.
This study establishes the principle that broadly neutralizing antibodies can suppress HIV-1 viraemia to levels that are below detection in humanized mice for prolonged periods of time. Their efficacy as therapeutics and their long-term effects on HIV-1 infection in humans can only be evaluated in clinical trials.
METHODS SUMMARY
Mice. Human fetal livers were procured from Advanced Bioscience Resources (ABR), Inc. NOD Rag1
2/2

Il2rg
null mice (The Jackson Laboratory) were irradiated with 100 cGy and reconstituted by injecting 1.5-2 3 10 5 human CD34 1 haematopoietic stem cells (HSCs) intrahepatically. Eight or more weeks after CD34 1 HSC injection, mice were infected intraperitoneally with HIV-1 YU2 (57.5 ng p24). Viral load was determined 14-20 days after infection and mice with viral loads .4 3 10 3 copies ml 21 were subjected to experiments. All experiments were performed with authorization from the Institutional Review Board and the IACUC at The Rockefeller University. Measuring HIV-1 viral load. Total RNA was extracted from 100 ml EDTAplasma and samples were analysed for HIV-1 RNA by qRT-PCR. Primers and an amplicon-specific probe targeted a conserved region within the HIV-1 59 long terminal repeat. Forward and reverse primer sequences were 59-GCCTC AATAAAGCTTGCCTTGA-39 and 59-GGCGCCACTGCTAGAGATTTT-39, respectively 29 . The internal probe (59-AAGTAGTGTGTGCCCGTCTGTTRT KTGACT-39) 29 contained a 59 6-carboxyfluorescein reporter and an internal/39 ZEN-Iowa Black FQ double-quencher (Integrated DNA Technologies). The reaction mix was prepared using the TaqMan RNA-to-Ct 1-Step kit (Applied Biosystems). Cycle threshold (Ct) values were correlated to standard samples of known viral RNA copy number. The lower limit of detection was found at 800 HIV-1 RNA copies ml Fig. 5 ). Copies ml -1 Copies ml -1 Copies ml -1 Figure 3 | Viral rebound in HIV-1 YU2 -infected humanized mice after cessation of antibody therapy. Viral load in RNA copies ml 21 (blue, left y axis) and antibody concentration reactive to YU2 gp120 in mg ml 21 (orange, right y axis) over time (x axis) after the last antibody injection (day 0). The green dotted line indicates the viral load average of the control group (Fig. 1a) . a, Viral load and YU2 gp120-reactive antibody concentration after stopping tri-mix therapy in mice that effectively controlled viraemia below the limit of detection. mAb, monoclonal antibody. b, gp120 sequences illustrated as in Fig. 2b for viruses obtained after viral rebound from mice previously treated with tri-mix therapy. Vertical blue bars highlight sites in which selected mutations are able to confer resistance (Supplementary Table 3a and Supplementary Fig. 8 ). c, Viral load and YU2 gp120-reactive antibody concentration after stopping penta-mix therapy. d, gp120 sequences for viruses obtained after rebound from mice previously treated with penta-mix therapy (Supplementary Table 3b ). e, Viral load of four mice re-treated with penta-mix therapy after viral rebound (c). Treatment period is highlighted in grey. Mouse numbers correspond to the mice in c.
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HIV-1 envelope sequence analysis. cDNA was generated from isolated RNA (Superscript III Reverse Transcriptase, Invitrogen) and amplified by nested PCR using gp120 YU2 -specific primers. PCR amplicons were gel purified and cloned using a TOPO-TA cloning kit (Invitrogen). Sequence reads were assembled using Geneious Pro software version 5.5.6 (Biomatters Ltd.) and aligned to gp120 YU2 (accession number M93258). All residues were numbered according to HXBc2 (http://www.hiv.lanl.gov/content/sequence/LOCATE/locate.html).
Full Methods and any associated references are available in the online version of the paper.
